ArticleNature2025
Lithium deficiency and the onset of Alzheimer's disease.
Abstract read
In one paragraph
Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed.
- Low-Dose Lithium for Mild Cognitive Impairment: A Pilot Randomized Clinical Trial.JAMA neurology · 2026Trial
- RNA G-quadruplex-protein interactions: from nuclear RNA processing to cytoplasmic stress response and neurodegeneration.RNA biology · 2026Review
- Review
- The lithium-magnesium-zinc axis under stress: regulation of N-glycosylation-linked proteostasis and Alzheimer's disease.Inflammopharmacology · 2026Review
- Lithium chloride in vitro treatment shows potential to rescue the neuronal phenotype caused by WDFY3 haploinsufficiency.Molecular psychiatry · 2026Article
- Manifestations of Lithium Deficiency in the Human Body: What is Known to Date (A Narrative Review).Biological trace element research · 2026Review
- Lithium as a Potential Senostatic Agent in Central Nervous System Aging and Bipolar Disorder.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Blood metal signatures and their association with Alzheimer's disease risk and cognitive decline in an Egyptian cohort.Communications medicine · 2026Article
- Low-dose lithium, neuroprotection, and brain aging in bipolar disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- Review
- Revisiting the cognitive potential of lithium in alzheimer's disease: the role of cholinergic system and brain connectivity.Translational psychiatry · 2026Review
- Lithium as a Potential Neuroprotective Strategy in Glaucoma: Mechanisms and Therapeutic Perspectives.Biomolecules · 2026Review
- Chronic Lithium Exposure Reshapes PI3K-mTOR-linked Proteostatic Networks in the Hippocampus of an Alzheimer's Disease Mouse Model.Molecular neurobiology · 2026Article
- Zinc Differentially Modulates Tau Aggregation, Fibril Morphology, and Prion-like Seeding in a Construct-Dependent Manner.bioRxiv : the preprint server for biology · 2026Article
- Selenium's Emergence from the Pool of Potentially Essential Trace Elements.Biological trace element research · 2026Review
- Article
- Lithium effects on renal functioning: an expert opinion and management algorithm.International journal of bipolar disorders · 2026Article
- Metal Modulation of Oxytocin Structure, Function, and Receptor Interactions.European journal of inorganic chemistry · 2026Article
- Alzheimer's disease: from molecular pathways to therapies.Molecular biomedicine · 2026Review
- Programmed cell death: a promising management for Alzheimer's disease.Apoptosis : an international journal on programmed cell death · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Liviu AronDepartment of Genetics, Harvard Medical School, Boston, MA, USA.
Zhen Kai NgianDepartment of Genetics, Harvard Medical School, Boston, MA, USA.
Chenxi QiuDepartment of Genetics, Harvard Medical School, Boston, MA, USA.
Jaejoon ChoiDepartment of Genetics, Harvard Medical School, Boston, MA, USA.
Marianna LiangDepartment of Genetics, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-6702-3256
Derek M DrakeDepartment of Genetics, Harvard Medical School, Boston, MA, USA.
Sara E HamplovaDepartment of Genetics, Harvard Medical School, Boston, MA, USA.
Ella K LaceyDepartment of Genetics, Harvard Medical School, Boston, MA, USA.ORCID 0009-0003-3863-5554
Perle RocheDepartment of Genetics, Harvard Medical School, Boston, MA, USA.
Monlan YuanDepartment of Genetics, Harvard Medical School, Boston, MA, USA.
Saba S HazavehDepartment of Genetics, Harvard Medical School, Boston, MA, USA.
Eunjung A LeeDivision of Genetics and Genomics, Boston Children's Hospital, Boston, MA, USA.
David A BennettRush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA.
Bruce A YanknerDepartment of Genetics, Harvard Medical School, Boston, MA, USA. bruce_yankner@hms.harvard.edu.ORCID 0009-0008-8982-225X
Funding
SUPPLEMENT TO RUSH ALZHEIMERS DISEASE CENTER COREP30AG010161 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BARNES, LISA L · 1991 to 2020
$49.1MEPIDEMIOLOGY OF NEURAL RESERVE AND NEUROBIOLOGY IN AGINGR01AG017917 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 2001 to 2023
$43.3MRush Alzheimer's Disease Research CenterP30AG072975 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI Lisa L Barnes, Julie A. Schneider · 2021 to 2026
$24.7MRISK FACTORS, PATHOLOGY, AND CLINICAL EXPRESSIONS OF ADR01AG015819 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 1998 to 2024
$21.4MMulti-omic network-directed proteoform discovery, dissection and functional validation to prioritize novel AD therapeutic targetsU01AG061356 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BENNETT, DAVID ALAN, DE JAGER, PHILIP L · 2018 to 2022
$13.7MPathway discovery, validation and compound identification for Alzheimer's disease - SupplementU01AG046152 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BENNETT, DAVID ALAN, DE JAGER, PHILIP L · 2013 to 2017
$13.6MTargeting a Novel Regulator of Brain Aging and Alzheimer's Disease (ADMINISTRATIVE SUPPLEMENT- SAGE)R01AG046174 · NIA · HARVARD MEDICAL SCHOOL · PI TSAI, LI-HUEI, YANKNER, BRUCE A · 2014 to 2018
$4.9MTargeting REST in Alzheimer's DiseaseR01AG069042 · NIA · HARVARD MEDICAL SCHOOL · PI YANKNER, BRUCE A · 2021 to 2025
$4.5MMechanism for endogenous retroelements to mimic ancient exogenous identities in aging and diseased human tissueDP2AG072437 · NIA · BOSTON CHILDREN'S HOSPITAL · PI LEE, EUNJUNG ALICE · 2020 to 2020
$2.7MThe role of somatic mutation in neurodegenerative diseaseK01AG051791 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI LEE, EUNJUNG ALICE · 2016 to 2020
$655kNIA NIH HHS DP2 AG072437NIA NIH HHS K01 AG051791NIA NIH HHS P30 AG010161NIA NIH HHS P30 AG072975NIA NIH HHS R01 AG015819NIA NIH HHS R01 AG017917NIA NIH HHS R01 AG046174NIA NIH HHS R01 AG069042NIA NIH HHS U01 AG046152NIA NIH HHS U01 AG061356
Abstract
The earliest molecular changes in Alzheimer's disease (AD) are poorly understood
Indexed as
Alzheimer DiseaseLithiumAgedAgingAmyloid beta-PeptidesAnimalsAxonsBrainCognitive DysfunctionDisease Models, AnimalFemaleGlycogen Synthase Kinase 3 betaHumansMaleMiceMicrogliaAmyloid beta-PeptidesGlycogen Synthase Kinase 3 betaGSK3B protein, humanGsk3b protein, mouseLithiumtau Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.